| ID Source | ID |
|---|---|
| PubMed CID | 11751305 |
| CHEMBL ID | 516110 |
| SCHEMBL ID | 2923319 |
| MeSH ID | M0528266 |
| Synonym |
|---|
| 5-amido-pyrrolopyrazole 3 |
| 4-(4-methylpiperazin-1-yl)-n-{5-[2-(thiophen-2-yl)acetyl]-1h,4h,5h,6h-pyrrolo[3,4-c]pyrazol-3-yl}benzamide |
| 2J4Z |
| 4-(4-methyl-piperazin-1-yl)-n-[5-(2-thiophen-2-yl-acetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-benzamide |
| 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 15 |
| chembl516110 , |
| bdbm12107 |
| pha-680626 |
| SCHEMBL2923319 |
| 4-(4-methylpiperazin-1-yl)-n-[5-(2-thiophen-2-yl-acetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]benzamide |
| 398493-74-8 |
| 4-(4-methylpiperazin-1-yl)-n-(5-(2-(thiophen-2-yl)acetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)benzamide. |
| 4-(4-methylpiperazin-1-yl)-n-[5-(2-thiophen-2-ylacetyl)-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]benzamide |
| 4-(4-methylpiperazin-1-yl)-n-(5-(2-(thiophen-2-yl)acetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)benzamide |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Aurora kinase A | Homo sapiens (human) | IC50 (µMol) | 0.0650 | 0.0000 | 0.4620 | 8.6000 | AID1796852; AID1796975; AID353619 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | IC50 (µMol) | 0.0646 | 0.0001 | 0.7128 | 10.0000 | AID743664 |
| Breakpoint cluster region protein | Homo sapiens (human) | IC50 (µMol) | 0.0646 | 0.0003 | 0.6200 | 10.0000 | AID743664 |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | IC50 (µMol) | 0.5300 | 0.0001 | 0.7734 | 9.0000 | AID387406 |
| Aurora kinase B | Homo sapiens (human) | IC50 (µMol) | 0.0650 | 0.0003 | 0.9634 | 9.8000 | AID1796975 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1796852 | Kinase SPA Assay from Article 10.1021/jm049076m: \\Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.\\ | 2005 | Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8 | Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. |
| AID1796975 | Kinase SPA Assay from Article 10.1021/jm060897w: \\1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.\\ | 2006 | Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24 | 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. |
| AID387406 | Inhibition of PLK1 | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors. |
| AID743664 | Inhibition of BCR-ABL kinase (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8 | BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives. |
| AID353619 | Inhibition of aurora A kinase | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | Discovery and development of aurora kinase inhibitors as anticancer agents. |
| AID353650 | Antiproliferative activity against human HCT116 cells assessed as BrdU incorporation after 72 hrs | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | Discovery and development of aurora kinase inhibitors as anticancer agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||